A Phase 2 interventional study of Ruconest in Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) and Covid19, sponsored by IMMUNOe Research Centers. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by IMMUNOe Research Centers · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.
Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2021, is one of 12 in phase 2, and was the 57th registered.
264 studies on the registry are indexed under Fatigue Syndrome, Chronic; 62 are open to participants now.
Browse Fatigue Syndrome, Chronic studies →21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:
Fred Friedberg · Sites in United States
Ages 18–65
University of Alabama at Birmingham · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
IMMUNOe Research Centers · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Fatigue Syndrome, Chronic studies recruiting now, 18 (41%) set no upper age limit and 20 (45%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 17 · Phase 3 1 · Phase 4 5
First in 1994; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 178 interventional studies indexed under Fatigue Syndrome, Chronic.
Median enrollment 50 across the 58 interventional studies, 152 across the 26 observational. Of the 47 that completed or were terminated, 15 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 86 have an industry lead sponsor. The 10 most frequent:
IMMUNOe Research Centers is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
IMMUNOe Research Centers has 2 studies filed under Fatigue Syndrome, Chronic — fewer than ten, so there is no comparison to draw.
10 of the studies in Fatigue Syndrome, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06585254Icahn School of Medicine at Mount SinaitVNS in Long COVID-19 | 2026-12-31 |
| NCT04049331Seattle Institute for Biomedical and Clinical ResearchTestosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone | 2027-01-30 |
| NCT04542161Weill Medical College of Cornell UniversityAssessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2027-04-30 |
| NCT07600320Icahn School of Medicine at Mount SinaiFareon Open Label Device Clinical Trial | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
This study will last approximately 19 weeks including 16 infusions total, each one week apart. This is to help patients that have developed "Post-Viral Fatigue Syndrome" which can include symptoms such as: extreme fatigue, lost of taste, brain fog, and/or seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV Ruconest
Drug: Ruconest
Placebo
Drug: Ruconest
C1 Esterase Inhibitor
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Time frame: Week 0
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Time frame: Week 9
Neuropsychological Measures (BRIEF-A)
Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)
Time frame: Week 17
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time frame: Week 0
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time frame: Week 9
Neuropsychological Measures (RBANS)
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time frame: Week 17
Neuropsychological Measures (BDI II)
Beck Depression Inventory II (BDI II)
Time frame: Week 0
Neuropsychological Measures (BDI II)
Beck Depression Inventory II (BDI II)
Time frame: Week 9
Neuropsychological Measures (BDI II)
Beck Depression Inventory II (BDI II)
Time frame: Week 17
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 0
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 9
Neuropsychological Measures (MoCA)
Montreal Cognitive Assessment (MoCA)
Time frame: Week 17
Patient-Rate Questionnaires (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 0
Patient-Rate Questionnaires (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 5
Patient-Rate Questionnaires (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 9
Patient-Rate Questionnaires (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 14
Patient-Rate Questionnaires (FSS)
Fatigue Severity Scale (FSS)
Time frame: Week 17
Patient-Rate Questionnaires (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 0
Patient-Rate Questionnaires (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 5
Patient-Rate Questionnaires (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 9
Patient-Rate Questionnaires (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 14
Patient-Rate Questionnaires (MIDAS)
Migraine Disability Assessment (MIDAS)
Time frame: Week 17
Patient-Rate Questionnaires (HIT)
Headache Impact Scale (HIT)
Time frame: Week 0
Patient-Rate Questionnaires (HIT)
Headache Impact Scale (HIT)
Time frame: Week 5
Patient-Rate Questionnaires (HIT)
Headache Impact Scale (HIT)
Time frame: Week 9
Patient-Rate Questionnaires (HIT)
Headache Impact Scale (HIT)
Time frame: Week 14
Patient-Rate Questionnaires (HIT)
Headache Impact Scale (HIT)
Time frame: Week 17
Patient-Rate Questionnaires (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 0
Patient-Rate Questionnaires (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 5
Patient-Rate Questionnaires (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 9
Patient-Rate Questionnaires (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 14
Patient-Rate Questionnaires (Activities)
Activities of Daily Living Sliding Scale and Questionnaire
Time frame: Week 17
Patient-Rate Questionnaires (SF)
SF McGill Pain Questionnaire
Time frame: Week 0
Patient-Rate Questionnaires (SF)
SF McGill Pain Questionnaire
Time frame: Week 5
Patient-Rate Questionnaires (SF)
SF McGill Pain Questionnaire
Time frame: Week 9
Patient-Rate Questionnaires (SF)
SF McGill Pain Questionnaire
Time frame: Week 14
Patient-Rate Questionnaires (SF)
SF McGill Pain Questionnaire
Time frame: Week 17
Patient-Rate Questionnaires (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 0
Patient-Rate Questionnaires (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 5
Patient-Rate Questionnaires (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 9
Patient-Rate Questionnaires (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 14
Patient-Rate Questionnaires (GSRS)
Gastrointestinal Symptoms Rating Scale (GSRS)
Time frame: Week 17
Patient-Rate Questionnaires (SF-36)
SF-36
Time frame: Week 0
Patient-Rate Questionnaires (SF-36)
SF-36
Time frame: Week 5
Patient-Rate Questionnaires (SF-36)
SF-36
Time frame: Week 9
Patient-Rate Questionnaires (SF-36)
SF-36
Time frame: Week 14
Patient-Rate Questionnaires (SF-36)
SF-36
Time frame: Week 17
Neurological Exam (0)
Complete neurological examination
Time frame: Week 0
Neurological Exam (9)
Complete neurological examination
Time frame: Week 9
Neurological Exam (17)
Complete neurological examination
Time frame: Week 17
Immunological Biomarkers (Toll)
Toll Like Receptor Function Assay
Time frame: Week 1
Immunological Biomarkers (Toll)
Toll Like Receptor Function Assay
Time frame: Week 9
Immunological Biomarkers (Toll)
Toll Like Receptor Function Assay
Time frame: Week 17
Immunological Biomarkers (GAD)
GAD-65
Time frame: Week 1
Immunological Biomarkers (GAD)
GAD-65
Time frame: Week 9
Immunological Biomarkers (GAD)
GAD-65
Time frame: Week 17
Immunological Biomarkers (Com)
Complement Panel (C4, C1-INH, C1-INH Function)
Time frame: Week 1
Immunological Biomarkers (Com)
Complement Panel (C4, C1-INH, C1-INH Function)
Time frame: Week 9
Immunological Biomarkers (Com)
Complement Panel (C4, C1-INH, C1-INH Function)
Time frame: Week 17
Immunological Biomarkers (Ig)
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Time frame: Week 1
Immunological Biomarkers (Ig)
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Time frame: Week 9
Immunological Biomarkers (Ig)
Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)
Time frame: Week 17
Immunological Biomarkers (IgG)
Immunoglobulins G, Subclasses (1-4)
Time frame: Week 1
Immunological Biomarkers (IgG)
Immunoglobulins G, Subclasses (1-4)
Time frame: Week 9
Immunological Biomarkers (IgG)
Immunoglobulins G, Subclasses (1-4)
Time frame: Week 17
Immunological Biomarkers (TH/TH)
TH1/TH2 Cytokine Levels
Time frame: Week 1
Immunological Biomarkers (TH/TH)
TH1/TH2 Cytokine Levels
Time frame: Week 9
Immunological Biomarkers (TH/TH)
TH1/TH2 Cytokine Levels
Time frame: Week 17
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Mar 2024, 38 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Conestat alfa
IMMUNOe Research Centers